文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

美国医院疑似社区起病脓毒症经验性广谱抗生素使用趋势

Trends in Empiric Broad-Spectrum Antibiotic Use for Suspected Community-Onset Sepsis in US Hospitals.
PubMed 文献 · JAMA Netw Open · 2024-06-03
一句话结论2017至2021年美国241家医院中,疑似社区起病脓毒症患者的经验性抗MRSA或抗假单胞菌β-内酰胺类使用比例从63.0%升至66.7%,而耐药菌分离率从9.6%降至7.3%。

这项横断面研究利用美国241家医院PINC AI医疗数据库,纳入2017至2021年收治的18岁及以上疑似社区起病脓毒症成人患者,定义为入院时留取血培养、测定乳酸并静脉使用抗生素。结果显示,疑似脓毒症患者占全部住院的14.3%,其中65.1%接受了经验性抗MRSA或抗假单胞菌β-内酰胺类治疗,且这两类药物占全院总用药天数的约一半。经验性广谱用药比例从2017年63.0%升至2021年66.7%(调整后OR每年1.03,95%CI 1.03-1.04),但耐药菌分离率从9.6%降至7.3%(调整后OR每年0.87,95%CI 0.87-0.88),接受广谱治疗者中90.5%无耐药菌。提示经验性广谱抗生素使用增加与耐药菌低分离率之间存在落差。

要点

  • 疑似社区起病脓毒症患者占住院14.3%,其中65.1%接受经验性抗MRSA或抗假单胞菌β-内酰胺类治疗,34.8%两者联用。
  • 疑似脓毒症患者占全院抗MRSA抗生素天数的50.1%、抗假单胞菌β-内酰胺类天数的49.3%。
  • 经验性广谱用药比例从2017年63.0%升至2021年66.7%(调整后OR每年1.03,95%CI 1.03-1.04)。
  • 耐药菌分离率仅7.3%,且从2017年9.6%降至2021年7.3%(调整后OR每年0.87,95%CI 0.87-0.88)。
  • 接受经验性广谱治疗者中90.5%无耐药菌,该比例从2017年88.0%升至2021年91.6%(调整后OR每年1.12,95%CI 1.11-1.13)。

适用人群与场景

  • 2017至2021年收治于241家美国医院的18岁及以上成人,符合疑似社区起病脓毒症定义:入院时留取血培养、测定乳酸并静脉使用抗生素。

诊断标准与关键阈值

  • 疑似社区起病脓毒症定义:入院时留取血培养、测定乳酸并静脉使用抗生素。
  • 回顾性判断经验性广谱治疗可能不必要: hospital day 4前临床培养未分离出β-内酰胺类耐药革兰阳性菌或头孢曲松耐药革兰阴性菌。

研究设计与关键结果

  • 研究类型:横断面研究,使用美国241家医院PINC AI医疗数据库,纳入6 272 538例住院,其中894 724例(14.3%)为疑似社区起病脓毒症;中位年龄66岁(IQR 53-78),男性443 465例(49.6%),Black 106 095例(11.9%),Hispanic 65 763例(7.4%),White 653 907例(73.1%)。
  • 在疑似脓毒症患者中,582 585例(65.1%)接受经验性抗MRSA(379 987例,42.5%)或抗假单胞菌β-内酰胺类(513 811例,57.4%)治疗,311 213例(34.8%)两者联用。
  • 疑似脓毒症患者占全院抗MRSA抗生素天数的1 573 673/3 141 300(50.1%),占抗假单胞菌β-内酰胺类天数的2 569 518/5 211 745(49.3%)。
  • 2017至2021年,接受抗MRSA或抗假单胞菌治疗的比例从63.0%(82 731/131 275)升至66.7%(101 003/151 435),调整后OR每年1.03(95%CI 1.03-1.04)。
  • 耐药菌分离共65 434例(7.3%),其中革兰阳性30 617例(3.4%),革兰阴性38 844例(4.3%);耐药菌分离比例从9.6%降至7.3%(调整后OR每年0.87,95%CI 0.87-0.88)。
  • 接受经验性抗MRSA和/或抗假单胞菌治疗的患者中,无耐药菌者527 356/582 585例(90.5%),该比例从2017年88.0%升至2021年91.6%(调整后OR每年1.12,95%CI 1.11-1.13)。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Little is known about the degree to which suspected sepsis drives broad-spectrum antibiotic use in hospitals, what proportion of antibiotic courses are unnecessarily broad in retrospect, and whether these patterns are changing over time.

OBJECTIVE: To describe trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used clinical data from adults admitted to 241 US hospitals in the PINC AI Healthcare Database. Eligible participants were aged 18 years or more and were admitted between 2017 and 2021 with suspected community-onset sepsis, defined by a blood culture draw, lactate measurement, and intravenous antibiotic administration on admission.

EXPOSURES: Empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) and/or antipseudomonal β-lactam agent use.

MAIN OUTCOMES AND MEASURES: Annual rates of empiric anti-MRSA and/or antipseudomonal β-lactam agent use and the proportion that were likely unnecessary in retrospect based on the absence of β-lactam resistant gram-positive or ceftriaxone-resistant gram-negative pathogens from clinical cultures obtained through hospital day 4. Annual trends were calculated using mixed-effects logistic regression models, adjusting for patient and hospital characteristics.

RESULTS: Among 6 272 538 hospitalizations (median [IQR] age, 66 [53-78] years; 443 465 male [49.6%]; 106 095 Black [11.9%], 65 763 Hispanic [7.4%], 653 907 White [73.1%]), 894 724 (14.3%) had suspected community-onset sepsis, of whom 582 585 (65.1%) received either empiric anti-MRSA (379 987 [42.5%]) or antipseudomonal β-lactam therapy (513 811 [57.4%]); 311 213 (34.8%) received both. Patients with suspected community-onset sepsis accounted for 1 573 673 of 3 141 300 (50.1%) of total inpatient anti-MRSA antibiotic days and 2 569 518 of 5 211 745 (49.3%) of total antipseudomonal β-lactam days. Between 2017 and 2021, the proportion of patients with suspected sepsis administered anti-MRSA or antipseudomonal therapy increased from 63.0% (82 731 of 131 275 patients) to 66.7% (101 003 of 151 435 patients) (adjusted OR [aOR] per year, 1.03; 95% CI, 1.03-1.04). However, resistant organisms were isolated in only 65 434 cases (7.3%) (30 617 gram-positive [3.4%], 38 844 gram-negative [4.3%]) and the proportion of patients who had any resistant organism decreased from 9.6% to 7.3% (aOR per year, 0.87; 95% CI, 0.87-0.88). Most patients with suspected sepsis treated with empiric anti-MRSA and/or antipseudomonal therapy had no resistant organisms (527 356 of 582 585 patients [90.5%]); this proportion increased from 88.0% in 2017 to 91.6% in 2021 (aOR per year, 1.12; 95% CI, 1.11-1.13).

CONCLUSIONS AND RELEVANCE: In this cross-sectional study of adults admitted to 241 US hospitals, empiric broad-spectrum antibiotic use for suspected community-onset sepsis accounted for half of all anti-MRSA or antipseudomonal therapy; the use of these types of antibiotics increased between 2017 and 2021 despite resistant organisms being isolated in less than 10% of patients treated with broad-spectrum agents.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Rhee C, Chen T, Kadri SS, et al. Trends in Empiric Broad-Spectrum Antibiotic Use for Suspected Community-Onset Sepsis in US Hospitals. JAMA Netw Open. 2024. PMID: 38935374. doi:10.1001/jamanetworkopen.2024.18923

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。